mNGF结合免疫球蛋白治疗急性脱髓鞘病的疗效  

Efficacy of mNGF combined with immunoglobulin in treating acute demyelinating disease

作　　者：王爱滨 李飞飞 陈保增 陈孝伟[1] 郝强[1] 陶伟[1] WANG Ai-bin;LI Fei-fei;CHEN Bao-zeng;CHEN Xiao-wei;HAO Qiang;TAO Wei(Department of Neurology,the Second People's Hospital of Liaocheng,Liaocheng Second Hospital Affiliated to Shandong First Medical University,Linqing 252600,Shandong,China;Department of Pediatric Medicine,the Second People's Hospital of Liaocheng,Liaocheng Second Hospital Affiliated to Shandong First Medical University,Linqing 252600,Shandong,China;Department of Cardiology,the Second People's Hospital of Liaocheng,Liaocheng Second Hospital Affiliated to Shandong First Medical University,Linqing 252600,Shandong,China)

机构地区：[1]聊城市第二人民医院·山东第一医科大学附属聊城二院神经内科,山东临清252600 [2]聊城市第二人民医院·山东第一医科大学附属聊城二院小儿内科,山东临清252600 [3]聊城市第二人民医院·山东第一医科大学附属聊城二院心内科,山东临清252600

出　　处：《川北医学院学报》2024年第4期484-487,共4页Journal of North Sichuan Medical College

基　　金：山东省中医药科技发展计划项目(2019-0912)。

摘　　要：目的:探讨鼠神经生长因子(mNGF)结合免疫球蛋白治疗急性脱髓鞘病疗效及其对患者神经功能和血清尿酸(UA)、同型半胱氨酸(Hcy)水平的影响。方法:选取70例急性脱髓鞘病患者为研究对象,根据治疗方案不同分为免疫组与mNGF组,每组各35例。免疫组患者给予免疫球蛋白治疗;mNGF组患者给予免疫球蛋白联合mNGF治疗。比较两组患者临床疗效,治疗前后肢体与神经功能[肢体功能评分(Hughes)与斯堪的那维亚卒中量表(SSS)评分]、电生理指标[运动神经传导速度(MCV)、复合肌肉动作电位(CMAP)波幅、F波潜伏期、感觉神经传导速度(SCV)、感觉神经动作电位(SNAP)波幅]、血清UA与Hcy水平及不良反应发生情况。结果:mNGF组临床疗效高于免疫组(P<0.05);治疗后,两组患者Hughes、SSS、F波潜伏期、Hcy均下降(P<0.05),且mNGF组显著低于免疫组(P<0.05);MCV、CMAP波幅、SCV、SNAP波幅、UA均上升(P<0.05),且mNGF组高于免疫组(P<0.05)。两组患者治疗期间不良反应发生率无统计学差异(P>0.05)。结论:mNGF联合免疫球蛋白可有效提高急性脱髓鞘病患者的治疗疗效,且安全好,值得临床推广使用。Objective:To explore the efficacy of mouse nerve growth factor(mNGF)combined with immunoglobulin in the treatment of acute demyelinating disease and its influence on neurological function and levels of serum uric acid(UA)and homocysteine(Hcy).Methods:70 patients with acute demyelinating disease were selected as the research subjects.According to different treatment regimens,they were divided into immune group and mNGF group,35 cases in each group.Patients in the immune group were treated with immunoglobulin therapy,and patients in the mNGF group were treated with immunoglobulin combined with mNGF.The clinical efficacy,limb function and neurological function[Hughes and Scandinavian Stroke Scale(SSS)scores],electrophysiological indicators[motor nerve conduction velocity(MCV),compound muscle action potential(CMAP)amplitude,F-wave latency,sensory nerve conduction velocity(SCV),sensory nerve action potential(SNAP)amplitude],serum UA and Hcy levels before and after treatment and adverse drug reactions were compared between the two groups.Results:The clinical efficacy in mNGF group was higher than that in immune group(P<0.05).After treatment,the Hughes score,SSS score,F wave latency and Hcy in the two groups were decreased(P<0.05),and the above indicators in mNGF group were lower than those in immune group(P<0.05).The MCV,CMAP amplitude,SCV,SNAP amplitude and UA were increased in the two groups after treatment(P<0.05),and the above indicators were higher in mNGF group than those in immune group(P<0.05).There were no statistical differences in adverse drug reactions between both groups(P>0.05).Conclusion:mNGF combined with immunoglobulin can effectively improve the clinical symptoms in patients with acute demyelinating disease,and is safe and effective,worthy of clinical promotion and use.

关 键 词：鼠神经生长因子 免疫球蛋白 急性脱髓鞘病 神经功能 

分 类 号：R744.5[医药卫生—神经病学与精神病学]